



IFW

Patent
Attorney Docket No. 032796-217

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

John P. CARULLI et al.

Application No.: 10/731,739

Filing Date: December 10, 2003

Title: HIGH BONE MASS GENE OF 11q13.3

Group Art Unit: 1636

Examiner: Celine X. Qian

Confirmation No.: 5366

THIRD
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTERCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Enclosed is a THIRD Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620Date: October 5, 2004By 
Mercedes K. Meyer
Registration No. 44,939



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

John P. Carulli et al.)

Application No.: 10/731,739)

Filed: December 10, 2003)

For: HIGH BONE MASS GENE OF 11Q13.3)

Group Art Unit: 1636

Examiner: Celine X. Qian

Confirmation No.: 5366

THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date October 5, 2004

By: 

Mercedes K. Meyer
Registration No. 44,939

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/731,7391
Filing Date	December 10, 2003
First Named Inventor	John P. CARULLI et al.
Examiner Name	Celine X. Qian
Attorney Docket Number	032796-217

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Gong et al., "LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development," Cell 107, pp. 513-523, Cell Press, Cambridge, Massachusetts, 2001.
	Magoori et al., "Severe Hypercholesterolemia, Impaired Fat Tolerance, and Advanced Atherosclerosis in Mice Lacking Both Low Density Lipoprotein Receptor-related Protein 5 and Apolipoprotein E*," The Journal of Biological Chemistry 278(13) pp. 11331-11336, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, Maryland, 2003.
	Boyden et al., "HIGH BONE DENSITY DUE TO A MUTATION IN LDL-RECEPTOR-RELATED PROTEIN 5," The New England Journal of Medicine 346(20), pp. 1513-1521, Massachusetts Medical, Boston, Massachusetts, 2002.
	Van Wesenbeeck et al., "Six Novel Missense Mutations in the LDL Receptor-Related Protein 5 (LRP5) Gene in Different Conditions with an Increased Bone Density," Am. J. Human. Genet., 72, pp. 763-771, The University of Chicago Press, Chicago, Illinois, 2003.
	Little et al., "A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait," Am. J. Hum. Genet., 70, pp. 11-19, The University of Chicago Press, Chicago, Illinois, 2002.
	Babij et al., "High Bone Mass in Mice Expressing a Mutant LRP5 Gene," Journal of Bone and Mineral Research, 18, pp. 960-974, Mary Ann Liebert, New York, 2003.
	Mizuguchi et al., "LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density," J. Hum. Genet. 49, pp. 80-86, Springer Verlag, Tokyo, Japan, 2004.
	International Search Report dated August 10, 2004.

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.